New 'Double-Target' cell therapy tested for patients who have run out of options
NCT ID NCT04186520
Summary
This study is testing a new type of personalized cell therapy called CAR-T for adults with B-cell blood cancers that have come back or not responded to standard treatments. Doctors modify a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The main goals are to see if this approach is safe and if it can put these aggressive cancers into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin and Froedtert Hospital
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.